Cleared Traditional

K972969 - QUICK-DRAW CAPILLARY WHOLE BLOOD COLLECTION SYSTEM (FDA 510(k) Clearance)

Class I Hematology device.

K972969 · Innovative Medical Technologies, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1997
Decision
42d
Days
Class 1
Risk

K972969 is an FDA 510(k) clearance for the QUICK-DRAW CAPILLARY WHOLE BLOOD COLLECTION SYSTEM. Classified as Tube, Collection, Capillary Blood (product code GIO), Class I - General Controls.

Submitted by Innovative Medical Technologies, Inc. (Lenexa, US). The FDA issued a Cleared decision on September 22, 1997 after a review of 42 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.6150 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Innovative Medical Technologies, Inc. devices

Submission Details

510(k) Number K972969 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 11, 1997
Decision Date September 22, 1997
Days to Decision 42 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
71d faster than avg
Panel avg: 113d · This submission: 42d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GIO Tube, Collection, Capillary Blood
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 864.6150
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.